EANM’11 – CTE Session IV
October 17, 2011, 16:30 – 18:00
Radionuclides in Therapy in Neuroendocrinal Tumours
Moderators: T. Eriksen (Oslo)
|L. Bodei (Milan):
The Use of PRRT in Neuroendocrine Tumours
|J. Buscombe (Cambridge):
The Use of 131I-MIBG in Neuroendocrine Tumours
|F. Sudbrock (Koeln):
131I-MIBG – Dosimetry and Measurement for Dosimetric Purposes
Upon completion of this session the attendee will be able to:
- Describe the use of PRRT in therapy of neuroendocrine tumours.
- Describe the use of MIBG in therapy of neuroendocrine tumours.
- Understand the difference between the use of PRRT and MIBG.
- Understand the limitations in use of PRRT and MIBG for adults and children.
Neuroendocrine tumours (NET) are relatively rare tumours with relative high mortality (40%) and poor survival for children. Treatment should be individualized according to the tumour type. Somatostatin analogues 90Y-DOTATOC, 177LU-DOTOTATE (PRRT) and 131I-MIBG have been used for several years. In this session we will hear about how somatostatin analogues and 131I-MIBG are used as medical treatment. Will therapy using PRRT receptor together with other treatment improve the survival of patients with neuroendocrine tumours?
Neuroendocrine Tumours (NET), 131I-MIBG, 90Y DATATOC, 177LU-DOTATATE, Therapy, PRRT (Peptide Receptor Radionuclide Therapy)